Polyhexanide, from SIFI, could become the first approved treatment for acanthamoeba keratitis, while aflibercept could become the first biosimilar version of Eylea in the EU.

Samsung Bioepis has reported positive Phase III data for its SB12 proposed eculizumab biosimilar to Soliris, with the product showing equivalence in efficacy, safety, PK, PD and immunogenicity.

Education for healthcare professionals and real-world evidence will be important factors in building trust in Byooviz, Samsung Bioepis and Biogen have told Generics Bulletin, acknowledging it will “take some time” for ophthalmologists to grow more comfortable prescribing biosimilars.

In the first part of an exclusive two-part interview, Samsung Bioepis’ development division leader Kyung-Ah Kim and Biogen’s global head of biosimilars Ian Henshaw discuss how the firms are aiming to capitalize on their launch of the world’s first Lucentis biosimilar, Byooviz, in the US.